<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00140465</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. A00803</org_study_id>
    <nct_id>NCT00140465</nct_id>
  </id_info>
  <brief_title>75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)</brief_title>
  <official_title>A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test whether an increase of the maintenance dose of
      clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced
      platelet aggregation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients treated with coronary stents clopidogrel therapy is usually initiated with a 300
      to 600 mg loading dose. In the CREDO trial it was shown that a 300 mg loading dose results in
      a reduction of ischemic events after percutaneous coronary intervention (PCI) if given 6
      hours prior to the procedure. An antiplatelet effect similar to that achieved by chronic
      therapy with 75 mg/day is reached within 2 hours when the high 600 mg loading is
      administered. The 600 mg loading dose has been shown to be safe and effective in preventing
      thrombotic events following coronary stent implantation. Recently, it was shown that in
      patients with stable angina and administration of the 600 mg loading dose at least two hours
      prior to PCI concomitant therapy with a GP IIb/IIIa antagonist does not result in a further
      reduction of the incidence of thrombotic events. In contrast to a number of investigations
      with different loading doses, no trials have been performed comparing different clopidogrel
      maintenance doses. Recently, it was shown that administration of a 600 mg loading dose in
      patients already on chronic clopidogrel therapy (75 mg/day) results in an additional
      significant increase in inhibition of adenosine diphosphate (ADP-) induced platelet
      aggregation. Therefore, it is possible that an increase of the clopidogrel maintenance dose
      in patients with chronic clopidogrel therapy also results in a more pronounced inhibition of
      platelet aggregation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal ADP(5µmol/l)-induced platelet aggregation 30 days after the intervention</measure>
    <time_frame>30 days after the intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal ADP(20µmol/l)-induced platelet aggregation 30 days after the intervention</measure>
    <time_frame>30 days after the intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 inhibition measured by point-of-care test</measure>
    <time_frame>P2Y12 inhibition measured by point-of-care test</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg Clopidogrel Maintenance Doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg Clopidogrel Maintenance Doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>after PCI</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Iscover</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>after PCI</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Iscover</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic aspirin therapy who are treated with percutaneous coronary
             intervention at least 2 hours after administration of a 600 mg loading dose of
             clopidogrel

        Exclusion Criteria:

          -  Major alterations of blood count (particularly platelet count &lt; 100x10^9/l,
             haemoglobin &lt; 10 mg/dl

          -  Recent bleeding diathesis

          -  Presence of a hematologic or malignant disorder

          -  Oral anticoagulation with coumarin derivates

          -  Use of glycoprotein (GP) IIb/IIIa antagonists during the intervention or during the
             preceding 14 days

          -  Therapy with clopidogrel within the last 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas von Beckerath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Nov 20;288(19):2411-20. Erratum in: JAMA. 2003 Feb 26;289(8):987..</citation>
    <PMID>12435254</PMID>
  </reference>
  <reference>
    <citation>Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirschinger J, Schömig A. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv. 2002 Apr;55(4):436-41.</citation>
    <PMID>11948888</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004 Jan 15;350(3):232-8.</citation>
    <PMID>14724302</PMID>
  </reference>
  <reference>
    <citation>Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001 Jan;85(1):92-3.</citation>
    <PMID>11119474</PMID>
  </reference>
  <reference>
    <citation>Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002 Oct 1;106(14):1893-900.</citation>
    <PMID>12356647</PMID>
  </reference>
  <reference>
    <citation>Gorchakova O, von Beckerath N, Gawaz M, Mocz A, Joost A, Schömig A, Kastrati A. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J. 2004 Nov;25(21):1898-902.</citation>
    <PMID>15522468</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schömig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004 Oct 5;110(14):1916-9. Epub 2004 Jul 19.</citation>
    <PMID>15262828</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2005</study_first_posted>
  <last_update_submitted>November 13, 2007</last_update_submitted>
  <last_update_submitted_qc>November 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

